Onconic Therapeutics develops next-generation anti-cancer therapies that target signal delivery agents and DNA damage repair enzymes in cancer cells. By addressing high unmet medical needs, the company aims to secure at least two new drug approvals within three years, enhancing treatment options for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer cells often develop resistance to existing treatments by manipulating signal delivery pathways and DNA damage repair mechanisms. This resistance leads to high unmet medical needs and limits effective treatment options for cancer patients.
Solution
Onconic Therapeutics is developing next-generation anti-cancer therapies that target dysregulated signal delivery agents and DNA damage repair enzymes within cancer cells. By specifically inhibiting these mechanisms, the therapies aim to overcome resistance and improve treatment outcomes. The company focuses on identifying and developing drugs with high marketability potential to address unmet needs in cancer treatment. Their goal is to provide innovative therapies that can secure new drug approvals and enhance treatment options for patients.
Target Audience
The primary target audience includes cancer patients with high unmet medical needs and healthcare providers seeking more effective treatment options.
Features
- Focus on signal delivery agents and DNA damage repair enzymes as therapeutic targets
- Development of innovative cancer treatments to overcome resistance mechanisms
- Identification of drugs with high marketability potential